1-3 of 3
John D. Hood, PhD
Close
Sort by
Journal Articles

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Terra L. Lasho, MT, Christy Finke, John D. Hood, PhD, Richard Soll, PhD, Glenn Noronha, PhD, Ruben A. Mesa, MD, Catriona Jamieson, MD, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD
Journal: Blood
Blood (2007) 110 (11): 3541.
https://doi.org/10.1182/blood.V110.11.3541.3541
Published: 2007
Journal Articles

Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348.

John D. Hood, PhD, Marcela Alomia, Jon Cao, Ph.D., Chun Chow, Ph.D., Hanna Ehab, M.S., Lohse Dan, Ph.D., Mak Chi Ching, Ph.D., McPherson Andy, Ph.D., Noronha Glenn, Ph.D., Tam Betty, Ph.D., Zhu Hong, Ph.D., Richard Soll, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 2528.
https://doi.org/10.1182/blood.V110.11.2528.2528
Published: 2007
Journal Articles

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, MS, Annelie Abrahamsson, MS, Charlene Barroga, PhD, Edward Kavelerchik, MD, Jason R. Gotlib, MD MS, John D. Hood, PhD, Jeffrey Durocher, PhD, Chi Ching Mak, PhD, Glen Noronha, PhD, Richard Soll, PhD, Ayalew Tefferi, MD, Kenneth Kaushansky, MD, Catriona H.M. Jamieson, MD PhD
Journal: Blood
Blood (2007) 110 (11): 1526.
https://doi.org/10.1182/blood.V110.11.1526.1526
Published: 2007